SEHK:9887Biotechs
Nanjing Leads Biolabs (SEHK:9887) Stock Rally Meets Deepening Half Year Losses
Traders have been willing to pay up for Nanjing Leads Biolabs, with the stock up about 26% over the past month and closing at HK$67.60 before today’s reaction to its half year numbers. The headline from this biotech earnings release is not revenue growth. It is the depth of the ongoing loss, with H1 2026 net income excluding extra items at a loss of C¥221.9 million and basic earnings per share in negative territory again.
The question now is whether today’s price move reflects a cool headed...